Zoetis Inc. $ZTS Stock Holdings Lowered by Clear Harbor Asset Management LLC

Clear Harbor Asset Management LLC cut its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 90.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,397 shares of the company’s stock after selling 23,023 shares during the period. Clear Harbor Asset Management LLC’s holdings in Zoetis were worth $302,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its stake in Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after purchasing an additional 2,978 shares during the period. Empowered Funds LLC grew its position in Zoetis by 6.2% in the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after acquiring an additional 657 shares in the last quarter. Intech Investment Management LLC increased its position in Zoetis by 17.2% during the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after buying an additional 1,224 shares during the last quarter. Sivia Capital Partners LLC lifted its holdings in Zoetis by 73.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after purchasing an additional 1,422 shares during the last quarter. Finally, Glenview Trust co boosted its position in Zoetis by 11.8% during the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock worth $745,000 after purchasing an additional 506 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Activity at Zoetis

In related news, Director Frank A. Damelio purchased 6,650 shares of the stock in a transaction dated Wednesday, May 13th. The stock was bought at an average cost of $75.39 per share, with a total value of $501,343.50. Following the purchase, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. The trade was a 44.91% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Paul Bisaro bought 2,000 shares of the stock in a transaction on Wednesday, May 13th. The stock was purchased at an average cost of $75.88 per share, with a total value of $151,760.00. Following the purchase, the director directly owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This represents a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 11,650 shares of company stock worth $886,384 over the last ninety days. Company insiders own 0.22% of the company’s stock.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple law firms issued reminders and deadline notices tied to an ongoing securities fraud class action against Zoetis, alleging investors were harmed by false or misleading statements during the Jan. 14, 2025 to May 6, 2026 period. These headlines can weigh on sentiment because they raise legal overhang and potential financial/reputational risk.
• Negative Sentiment: Zoetis was reportedly downgraded after a steep broader market selloff, signaling weakening near-term sentiment from Wall Street and adding to pressure on the stock.
• Negative Sentiment: A bearish article highlighted lawsuits challenging the company’s companion-animal outlook, suggesting investors may be questioning growth assumptions for a key business segment.
• Neutral Sentiment: Zoetis presented at the 46th Annual William Blair Growth Stock Conference, which may help investors gauge management’s outlook and strategy, but no major new catalyst was highlighted in the transcript headline.
• Neutral Sentiment: One valuation-oriented piece argued Zoetis could be a deep-value opportunity with significant upside, which may support longer-term sentiment but is unlikely to outweigh today’s legal and rating-related headlines.

Analyst Ratings Changes

ZTS has been the topic of several recent analyst reports. BTIG Research reiterated a “buy” rating and issued a $160.00 target price on shares of Zoetis in a report on Thursday, February 26th. Argus reissued a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Stifel Nicolaus lowered their target price on Zoetis from $105.00 to $95.00 and set a “hold” rating on the stock in a report on Friday, May 22nd. UBS Group cut their price target on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a report on Friday, May 8th. Finally, Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. Six analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Zoetis currently has an average rating of “Hold” and a consensus target price of $133.92.

Zoetis Price Performance

Shares of Zoetis stock opened at $76.42 on Wednesday. Zoetis Inc. has a twelve month low of $72.38 and a twelve month high of $172.23. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The firm’s 50-day simple moving average is $103.52 and its 200-day simple moving average is $116.71. The firm has a market cap of $32.04 billion, a P/E ratio of 12.67, a price-to-earnings-growth ratio of 1.27 and a beta of 0.75.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The company’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter last year, the business earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, research analysts expect that Zoetis Inc. will post 6.89 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s payout ratio is currently 35.16%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.